ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2013
Sirtuin deacetylases as therapeutic targets in the nervous system.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Sirtuin Acetylation and Deacetylation: a Complex Paradigm in Neurodegenerative Disease.Molecular neurobiology · 2021Pooled it
- Computational Repurposing of Nilotinib and Radotinib as SIRT2 Inhibitors for Neurodegenerative Diseases.Journal of molecular neuroscience : MN · 2026Article
- HDACs targeting from traditional Chinese medicine: mechanisms and therapeutic potential in rheumatoid arthritis.Frontiers in pharmacology · 2026Review
- Enhanced Bioactive Compounds and Antioxidant Activity in Germinated Seeds of the New Peanut Variety.Biotech (Basel (Switzerland)) · 2025Article
- Cellular senescence: from homeostasis to pathological implications and therapeutic strategies.Frontiers in immunology · 2025Review
- Aspartame Causes Developmental Defects and Teratogenicity in Zebra Fish Embryo: Role of Impaired SIRT1/FOXO3a Axis in Neuron Cells.Biomedicines · 2024Article
- Targeting Cellular Senescence in Aging and Age-Related Diseases: Challenges, Considerations, and the Emerging Role of Senolytic and Senomorphic Therapies.Aging and disease · 2024Review
- Article
- Role of NADCellular and molecular neurobiology · 2023Review
- Transcriptional regulation ofMolecular medicine reports · 2022Article
- SIRT2 Inhibition Improves Functional Motor Recovery After Peripheral Nerve Injury.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Article
- Novel neuroprotective therapy with NeuroHeal by autophagy induction for damaged neonatal motoneurons.Theranostics · 2020Article
- Microglial Sirtuin 2 Shapes Long-Term Potentiation in Hippocampal Slices.Frontiers in neuroscience · 2020Article
- Dihydronicotinamide riboside is a potent NADThe Journal of biological chemistry · 2019Article
- Catalytic-independent neuroprotection by SIRT1 is mediated through interaction with HDAC1.PloS one · 2019Article
- High-altitude adaptation in humans: from genomics to integrative physiology.Journal of molecular medicine (Berlin, Germany) · 2017Review
- Targeting NAD+ in Metabolic Disease: New Insights Into an Old Molecule.Journal of the Endocrine Society · 2017Review
- Poly(ADP-ribose) polymerase 1 is a novel target to promote axonal regeneration.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Mitochondrial Sirt3 Expression is Decreased in APP/PS1 Double Transgenic Mouse Model of Alzheimer's Disease.Neurochemical research · 2015Article
- Looking above but not beyond the genome for therapeutics in neurology and psychiatry: epigenetic proteins and RNAs find a new focus.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Sirtuins are a conserved family of deacetylases whose activities are dependent on nicotinamide adenine dinucleotide (NAD+). Sirtuins act in different cellular compartments, such as the nucleus where they deacetylate histones and transcriptional factors, in the cytoplasm where they modulate cytoskeletal and signaling molecules, and in the mitochondria where they engage components of the metabolic machinery. Collectively, they tune metabolic processes to energy availability, and modulate stress responses, protein aggregation, inflammatory processes, and genome stability. As such, they have garnered much interest and have been widely studied in aging and age-related neurodegeneration. In this chapter, we review the identification of sirtuins and their biological targets. We focus on their biological mechanisms of action and how they might be regulated, including via NAD metabolism, transcriptional and posttranscriptional control, and as targets of pharmacological agents. Lastly, we highlight the numerous studies suggesting that sirtuins are efficacious therapeutic targets in neurodegenerative disease and injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.